# A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer

Source: https://onco.cc/trials/nct06892548/  
OnCo record `nct06892548` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of BNT324 and PM8002 in advanced solid tumours, run by BioNTech SE, now recruiting.

## Summary

A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer is a phase 1/2 interventional study registered as NCT06892548 by BioNTech SE, with 594 participants planned, started 2025-05-02 and due to reach its primary completion in 2028-09. Interventions recorded: BNT324 and BNT327.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06892548
- Phase: 1/2
- Setting: A Phase Ib/II, Multi-site, Open-label, Two-part Trial to Evaluate the Efficacy, Safety, Pharmacokinetics, and Recommended Combination Dose of BNT324 With BNT327 in Participants With Advanced Lung Cancer
- Sponsor: BioNTech SE
- Enrolled: 594

## Sources

- ClinicalTrials.gov NCT06892548: https://clinicaltrials.gov/study/NCT06892548

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [BNT324](https://onco.cc/drugs/bnt324/), [PM8002](https://onco.cc/drugs/pm8002/)
- companies: [BioNTech](https://onco.cc/companies/biontech/), [Duality Biotherapeutics](https://onco.cc/companies/dualitybio/)

---
JSON: https://onco.cc/api/v1/entities/nct06892548.json